Shahzeb ., Nasir Ali, Abdul Hadi, Ibrahim shah, Adnan Mehmood Gul, Jabar Ali, Mohammad Hafizullah


Background: Percutaneous coronary interventions are almost always preceded by the loading dose of platelets inhibiter drugs such as clopidogrel or prasugrel and followed by maintenance therapy to decrease the mortality and morbidity due to stent thrombosis. This study was conducted to compare the efficacy of clopidogrel and prasugrel for inhibiting platelet aggregation among patients undergoing elective percutaneous coronary intervention. Methods: This randomized controlled trial study was done in Department of Cardiology, Postgraduate Medical Institute Govt. Lady Reading Hospital Peshawar. A total of 148 patients were randomly allocated to either group-A containing 74 patients using clopidogrel or group-B containing 74 patients using prasugrel Results:. Group-A had 55 (74.3%) male and 19 (25.7%) females while group-B had 56(75.7%) males and 18(24.3%) females (p=0.85). Mean age was 54.9±11.2 years in group-A and was 57.7±8.7 years in group-B (p=0.09). Mean body weight was 71.8±6.4 Kg in group-A and 70.8±6.3 Kg in group-B (p=0.35). Mean Baseline platelet aggregation before drug administration was 10.43±1.9 ohm in group-A while 10.12±2.2 ohm in group-B (p=0.36). Mean Follow up platelet aggregation 6 hours after drug administration was 5.88±2.9 in group-A while it was 3.47±1.8 ohm in group-B (p=0.001). Mean Difference between basal and follow up platelet aggregation ±SD was 52.9649±24.77 in group-A while it was 82.25±14.34 in group-B (p=0.001). 63(85.15%) of group-A had inhibition of platelets aggregation >10% as compare to 72(97.3%) of group-B had inhibition of platelets aggregation >10% (p=0.009). Conclusion: Prasugrel is more efficacious than clopidogrel in term of inhibition of platelets aggregation.

Keywords: Clopidogrel, prasugrel, platelets aggregation

Full Text:



WHO Statistics Fact Sheet N 317, September 2011

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001–15.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome 450 genetic polymorphisms & the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic and clinical outcome. Circulation 2009;119(19):2553–60.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome 450 genetic polymorphisms and the response to clopidogrel .N Engl J Med 2009;360(4);354–62.

Duconge J, Cadilla CL, Renta JY, Silén-Rivera P, Piovanetti P, García-Berdecía R, et al. Prevalence of CYP2C19 Gene Polymorphisms in the Puerto Rican Population: a preliminary report. P R Health Sci J 2008;27(4):357–8.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, et al. Unstable Angina, NSTEMI and STEMI: Comparison of Antiplatelet Agents. Circulation 2009;120:1027–8

Bellemain-Appaix A, Montalescot G, Silvain J, Barthélémy O, Beygui F, Collet J, et al. Slow Response to Clopidogrel Predicts Low Response J Am Coll Cardiol 2010;55(8):815–22.

Khan H, Jan H, Hafizullah M. Study on clopidogrel in inhibition of platelet aggregation In suspected angina patients, treated with a daily dose of 75 mg of clopidogrel for 7 days. Iran J Pharm Res 2009;8(2):135–40.

Tomasello SD, Tello-Montoliu A, Angiolillo DJ. Prasugrel for thetreatment of coronary thrombosis: a review of pharmacological properties,indications for use and future development. Expert OpinInvestigDrugs 2011;20(1):119–33.

Michelson AD, Frelinger AL, Braunwald E,Downey WE, Angiolillo DJ, Xenopoulos NP, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30(14):1753–63.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, et al. A Comparative Evaluation of Prasugreland Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.J Assoc Physicians India 2013;61(2):114–6.

Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD,et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116(25):2923–32.

Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27(10):1166–73.

DasbiswasA,Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S. A Comparative Evaluation of Prasugrel and Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention J Assoc Physicians India 2013;61:28–40.

Serebruany VL, MideiMG ,Meilman H, Malinin AI , Lowry DR. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006;82(968):404–10

Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, KennedyM, et al. Determination of the active and inactive metabolitesof prasugrel in human plasma by liquid chromatography/tandemmass spectrometry. Rapid Commun Mass Spectrom 2007;21:169-79.

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd,Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazoleaffects prasugrel and clopidogrel pharmacokinetics and pharmacodynamicsdifferently. Clin Pharmacol Ther 2007;81:735–41.


  • There are currently no refbacks.

Contact Number: +92-992-382571

email: [jamc] [@] [ayubmed.edu.pk]